MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Search

Amgen Inc

Closed

SectorHealthcare

343.67 3.84

Overview

Share price change

24h

Current

Min

329.07

Max

343.83

Key metrics

By Trading Economics

Income

1.8B

3.2B

Sales

390M

9.6B

P/E

Sector Avg

25.574

89.037

EPS

5.64

Dividend yield

2.85

Profit margin

33.651

Employees

28,000

EBITDA

2.3B

5.9B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+5.24% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.85%

2.18%

Next Earnings

3 Feb 2026

Next Dividend date

6 Mar 2026

Next Ex Dividend date

13 Feb 2026

Market Stats

By TradingEconomics

Market Cap

18B

178B

Previous open

339.83

Previous close

343.67

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Amgen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Jan 2026, 15:14 UTC

Acquisitions, Mergers, Takeovers

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

19 Nov 2025, 21:55 UTC

Major Market Movers

Amgen Lung Cancer Drug Gets Full Approval From FDA

4 Nov 2025, 21:39 UTC

Earnings

Amgen Raises Fiscal Year Outlook After 3Q Profit, Sales Jump

5 Aug 2025, 20:51 UTC

Earnings

Amgen Posts Higher 2Q Profit, Revenue On Sales Growth Among Products

6 Jan 2026, 14:01 UTC

Acquisitions, Mergers, Takeovers

Amgen: Deal Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia >AMGN

6 Jan 2026, 14:01 UTC

Acquisitions, Mergers, Takeovers

Amgen Acquires Dark Blue Therapeutics in Transaction Valued at Up to $840 Million >AMGN

6 Jan 2026, 14:00 UTC

Acquisitions, Mergers, Takeovers

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE >AMGN

4 Nov 2025, 21:24 UTC

Earnings

Amgen Raises FY Outlook After 3Q Profit, Sales Jump

4 Nov 2025, 21:01 UTC

Earnings

Amgen 3Q Worldwide Prolia Sales $1.14B >AMGN

4 Nov 2025, 21:01 UTC

Earnings

Amgen 3Q Worldwide Enbrel Sales $580M >AMGN

4 Nov 2025, 21:01 UTC

Earnings

Amgen 3Q Worldwide XGEVA Sales $539M >AMGN

4 Nov 2025, 21:01 UTC

Earnings

Amgen 3Q Rev $9.56B >AMGN

4 Nov 2025, 21:01 UTC

Earnings

Amgen 3Q Adj EPS $5.64 >AMGN

4 Nov 2025, 21:01 UTC

Earnings

Amgen Sees FY Rev $35.8B-$36.6B >AMGN

4 Nov 2025, 21:01 UTC

Earnings

Amgen Sees FY Adj EPS $20.60-Adj EPS $21.40 >AMGN

4 Nov 2025, 21:01 UTC

Earnings

Amgen 3Q Net $3.22B >AMGN

4 Nov 2025, 21:01 UTC

Earnings

Amgen 3Q Worldwide Neulasta Sales $92M >AMGN

4 Nov 2025, 21:01 UTC

Earnings

Amgen Sees FY EPS $13.76-EPS $14.60 >AMGN

4 Nov 2025, 21:01 UTC

Earnings

Amgen 3Q EPS $5.93 >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen Sees FY Rev $35B-$36B >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen Sees FY EPS $10.97-EPS $12.11 >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen Sees FY Adj EPS $20.20-Adj EPS $21.30 >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Worldwide Prolia Sales $1.12B >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Worldwide XGEVA Sales $532M >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Net $1.43B >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Worldwide Enbrel Sales $604M >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Worldwide Neulasta Sales $82M >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Rev $9.2B >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q Adj EPS $6.02 >AMGN

5 Aug 2025, 20:01 UTC

Earnings

Amgen 2Q EPS $2.65 >AMGN

Peer Comparison

Price change

Amgen Inc Forecast

Price Target

By TipRanks

5.24% upside

12 Months Forecast

Average 348.33 USD  5.24%

High 425 USD

Low 280 USD

Based on 19 Wall Street analysts offering 12 month price targets forAmgen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

10

Buy

8

Hold

1

Sell

Technical Score

By Trading Central

270.44 / 276.44Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat